[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553229":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Shanghai Pharmaceuticals Holding Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SPH7854","EXPERIMENTAL",null,[13],"Drug: SPH7854",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","SPH7854： Orally, 50-3200mg",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Placebo：Orally；",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Qin Yu","CONTACT","0086-028-85501685","hxeyyb@126.com",[34],{"facility":35,"status":36,"city":37,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"West China Second University Hospital, Sichuan University","RECRUITING","Chengdu","China","CN",{"type":41,"coordinates":42},"Point",[43,44],104.06667,30.66667,{"lat":44,"lon":43},[47],{"name":29,"role":30,"phone":11,"phoneExt":11,"email":11},{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100553229","early-phase-1-a-clinical-study-of-sph7854-granules-in-healthy-subjects-100553229",false,"NCT06483373","A Clinical Study of SPH7854 Granules in Healthy Subjects.","A Single and Multiple Dose-escalation, and Food Effects of Phase I Clinical Study to Evaluate the Tolerability\u002FSafety\u002FPharmacokinetics of SPH7854 Granules in Healthy Subjects.","Inclusion Criteria:\n\n1. Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent；\n2. Healthy volunteers;\n3. Before receiving the investigational drug, the examination results were normal or clinically insignificant;\n4. Subjects who have no fertility plan\u002Fsperm donation\u002Fegg donation plan and voluntarily take effective contraceptive measures, from signing the informed consent to the prescribed time after the last dosing.\n\nExclusion Criteria:\n\n1. Female subjects who are breastfeeding or have positive pregnancy results;\n2. Subjects with chronic, unstable, or recurrent disease or surgery history who are judged by the investigator to be ineligible before signing informed consent;\n3. Subjects suffering from allergic diseases or having a history of severe allergies;\n4. Subjects who took the drug or food prohibited by the protocol prior to the first dose;\n5. Subjects with evidence of infection who could not be enrolled according to the investigator's judgement;\n6. Other circumstances that meet the protocol exclusion criteria.",true,"ALL","18 Years","45 Years",{"count":62,"type":63},111,"ESTIMATED","INTERVENTIONAL",[66],"EARLY_PHASE1","To evaluate the safety of SPH7854 in healthy subjects.",[69],"Inflammatory Bowel Disease","2026-04-29",{"date":72,"type":73},"2026-05-05","ACTUAL",{"date":75,"type":73},"2024-05-28",{"date":77,"type":63},"2026-12-31",{"name":5,"class":6},1]